trial

Acetazolamide for Treatment Resistant Schizophrenia

NCTId NCT04887792
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Recruiting
Enrollment 60 (estimated)
Sponsored by Vishwajit Nimgaonkar, MD PhD
Primary completion 2026-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2022-02-01
Primary completion
2026-06-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Acetazolamide

Sponsors

Vishwajit Nimgaonkar, MD PhDLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Vishwajit L. Nimgaonkar, M.D., Ph.D.Principal Investigator

Sites

2 total
Pittsburgh, United StatesBangalore, India

Linked catalysts

1
Acetazolamide for Treatment Resistant Schizophrenia — primary completion2026-06-30

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE1,PHASE2
Primary Completion Date
2026-06-30
Status
RECRUITING
relationships
The graph out of here
drug
Acetazolamide
drug
lead_sponsor
Vishwajit Nimgaonkar, MD PhD
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication
investigator
Vishwajit L. Nimgaonkar, M.D., Ph.D.
person